ArticleACS infectious diseases2021
Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant
Open access · greenAbstract read
In one paragraph
Article in ACS infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- The Quantification of Drug Accumulation within Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- Fermentative growth decreases the iron demand of Staphylococcus aureus.Journal of inorganic biochemistry · 2026Article
- Article
- Comprehensive biological evaluation of infuzide as a potent antimicrobial, alone and in combination with gentamicin, linezolid, and minocycline targeting MDRMicrobiology spectrum · 2025Article
- Combination therapy delays antimicrobial resistance after adaptive laboratory evolution ofAntimicrobial agents and chemotherapy · 2025Article
- Identification of Cysteine Metabolism Regulator (CymR)-Derived Pentapeptides as Nanomolar Inhibitors ofACS infectious diseases · 2025Article
- Impact of the pentose phosphate pathway on metabolism and pathogenesis of Staphylococcus aureus.PLoS pathogens · 2023Article
- Copper ions inhibit pentose phosphate pathway function in Staphylococcus aureus.PLoS pathogens · 2023Article
- Random Forest Model Predictions Afford Dual-Stage Antimalarial Agents.ACS infectious diseases · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Jimmy S PatelDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, 185 South Orange Ave, Newark, New Jersey 07103, United States.
Javiera NorambuenaDepartment of Biochemistry and Microbiology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey 08901, United States.
Hassan Al-TameemiDepartment of Biochemistry and Microbiology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey 08901, United States.
Yong-Mo AhnDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, 185 South Orange Ave, Newark, New Jersey 07103, United States.
Alexander L PerrymanDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, 185 South Orange Ave, Newark, New Jersey 07103, United States.
Xin WangDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, 185 South Orange Ave, Newark, New Jersey 07103, United States.ORCID 0000-0002-6930-3347
Samer S DaherDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, 185 South Orange Ave, Newark, New Jersey 07103, United States.
James OcciDepartment of Medicine, Center for Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Riccardo RussoDepartment of Medicine, Center for Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Steven ParkPublic Health Research Institute, Rutgers University - New Jersey Medical School, 225 Warren St, Newark, New Jersey 07103, United States.
Matthew ZimmermanPublic Health Research Institute, Rutgers University - New Jersey Medical School, 225 Warren St, Newark, New Jersey 07103, United States.
Hsin-Pin HoPublic Health Research Institute, Rutgers University - New Jersey Medical School, 225 Warren St, Newark, New Jersey 07103, United States.
David S PerlinPublic Health Research Institute, Rutgers University - New Jersey Medical School, 225 Warren St, Newark, New Jersey 07103, United States.
Véronique DartoisPublic Health Research Institute, Rutgers University - New Jersey Medical School, 225 Warren St, Newark, New Jersey 07103, United States.ORCID 0000-0001-9470-5009
Sean EkinsCollaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, North Carolina 27526, United States.ORCID 0000-0002-5691-5790
Pradeep KumarDepartment of Medicine, Center for Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Nancy ConnellDepartment of Medicine, Center for Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Jeffrey M BoydDepartment of Biochemistry and Microbiology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey 08901, United States.ORCID 0000-0001-7721-3926
Joel S FreundlichDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, 185 South Orange Ave, Newark, New Jersey 07103, United States.ORCID 0000-0002-3411-3455
Rutgers, The State University of New Jersey · USCollaborations Pharmaceuticals (United States) · US
Funding
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI ALLAND, DAVID · 2019 to 2023
$33.9MTherapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2018
$26.9MMechanisms of cellular respiration-dependent cell lysis and its impact on biofilm formation and disassembly in Staphylococcus aureus.R01AI139100 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI BOYD, JEFF M · 2018 to 2022
$1.9MProgram in Infection, Immunity and InflammationT32AI125185 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI SALGAME, PADMINI · 2016 to 2020
$747kNIAID NIH HHS R01 AI139100NIAID NIH HHS T32 AI125185NIAID NIH HHS U19 AI109713NIAID NIH HHS U19 AI142731
Abstract
We present the application of Bayesian modeling to identify chemical tools and/or drug discovery entities pertinent to drug-resistant
Indexed as
Methicillin-Resistant Staphylococcus aureusPharmaceutical PreparationsStaphylococcal InfectionsAnimalsBayes TheoremMiceStaphylococcus aureusPharmaceutical PreparationsAzoRBayesian modelingintrabacterial drug metabolismquinolineStaphylococcus aureusYceI
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.